These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29422794)

  • 21. Management and monitoring of pediatric inflammatory bowel disease in the Asia-Pacific region: A position paper by the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group: Surgical management, disease monitoring, and special considerations.
    Lee WS; Arai K; Alex G; Treepongkaruna S; Kim KM; Choong CL; Mercado KC; Darma A; Srivastava A; Aw MM;
    J Gastroenterol Hepatol; 2023 Apr; 38(4):510-522. PubMed ID: 36508314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active tuberculosis in inflammatory bowel disease patients: a case-control study.
    Freitas Cardoso de Azevedo M; Barros LL; Fernandes Justus F; Oba J; Soares Garcia K; de Almeida Martins C; de Sousa Carlos A; Arruda Leite AZ; Miranda Sipahi A; Queiroz NSF; Omar Mourão Cintra Damião A
    Therap Adv Gastroenterol; 2023; 16():17562848231179871. PubMed ID: 37435180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul.
    Nakase H; Keum B; Ye BD; Park SJ; Koo HS; Eun CS
    Intest Res; 2016 Jul; 14(3):231-9. PubMed ID: 27433145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
    Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S;
    J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis.
    Jun YK; Chun J; Kang EA; Lee HJ; Im JP; Kim JS
    Korean J Gastroenterol; 2019 Sep; 74(3):168-174. PubMed ID: 31554033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening.
    Giri S; Bhrugumalla S; Shukla A; Gangadhar S; Reddy S; Angadi S; Shinde L; Kale A
    Arab J Gastroenterol; 2024 Feb; ():. PubMed ID: 38383265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pan American Crohn's and Colitis Organization (PANCCO) and the Interamerican Society of Endoscopy (SIED) consensus on endoscopy in inflammatory bowel disease].
    Parra-Izquierdo V; Gil-Parada FL; Juliao-Baños F; Pavez-Ovalle C; Otero-Regino W; Frías-Ordoñez JS; Tchekmedyian A; Paredes-Méndez JE; Dorelo R; Ernest-Suárez K; Leites Madera M; Galiano MT; Pazos X; Jara Alba ML; Dias de Oliveira CM; Villa Ovalles K; Queraz R; Miranda MC; Arango Molano LA; Puentes Manosalva FE; Zaltman C; Florez-Sarmiento C; Flores C; Andrade Zamora D; Fluxa F; Veitia G
    Rev Gastroenterol Peru; 2024; 44(2):179-215. PubMed ID: 39019814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Hong SN; Kim HJ; Kim KH; Han SJ; Ahn IM; Ahn HS
    Aliment Pharmacol Ther; 2017 Jan; 45(2):253-263. PubMed ID: 27933686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul.
    Kim ES; Chen M; Lee J; Lee CK; Kim YS
    Intest Res; 2016 Jul; 14(3):224-30. PubMed ID: 27433144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease.
    Mack DR; Benchimol EI; Critch J; deBruyn J; Tse F; Moayyedi P; Church P; Deslandres C; El-Matary W; Huynh H; Jantchou P; Lawrence S; Otley A; Sherlock M; Walters T; Kappelman MD; Sadowski D; Marshall JK; Griffiths A
    Gastroenterology; 2019 Aug; 157(2):320-348. PubMed ID: 31320109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Recommendations for tuberculosis screening before and during treatment with tumour necrosis factor inhibitors].
    Mandić D; Curcić R; Radosavljević G; Damjanov N; Stefanović D; Mitić I; Dimić A
    Srp Arh Celok Lek; 2009; 137(3-4):211-6. PubMed ID: 19459572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease.
    Yamamoto-Furusho JK; Bosques-Padilla FJ; Martínez-Vázquez MA;
    Rev Gastroenterol Mex (Engl Ed); 2021; 86(1):70-85. PubMed ID: 33317930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
    Theis VS; Rhodes JM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement.
    Leung WK; Ng SC; Chow DK; Lao WC; Leung VK; Li MK; Hui YT; Ng SS; Hui AJ; Lai ST; Lam JT; Poon JT; Chan AO; Yuen H; Wu JC; ;
    Hong Kong Med J; 2013 Feb; 19(1):61-8. PubMed ID: 23378357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
    Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
    Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.